The kin-cohort study for estimating penetrance

被引:97
作者
Wacholder, S
Hartge, P
Struewing, JP
Pee, D
McAdams, M
Brody, L
Tucker, M
机构
[1] NCI, Biostat Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA
[2] Informat Management Syst, Rockville, MD USA
[3] Informat Management Syst, Silver Spring, MD USA
[4] Natl Human Genome Res Inst, Bethesda, MD USA
关键词
biometry; breast neoplasms; colon neoplasms; epidemiologic methods; genetics; Jews; ovarian neoplasms;
D O I
10.1093/aje/148.7.623
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
A cross-sectional study may be more feasible than a cohort or case-control study for examining the effect of a genetic mutation on cancer penetrance outside of cancer families. The kin-cohort design uses Volunteer probands selected from a population with a relatively high frequency of the mutations of interest. By considering the cancer risk in first-degree relatives of mutation-positive and -negative probands as a weighted average of the risk in carriers and noncarriers, with weights calculated assuming a known mode of inheritance, one can infer the penetrance of the mutations. The estimates of penetrance by age 70 years for three specific mutations in the BRCA1 and BRCA2 genes common among Ashkenazi Jews for the first occurrence of breast or ovary cancer is 63%. The kin-cohort design can be a useful tool for quickly estimating penetrance from volunteers in a setting in which the mutation prevalence is relatively high.
引用
收藏
页码:623 / 630
页数:8
相关论文
共 16 条
  • [1] AGE AT ONSET FOR FAMILIAL EPITHELIAL OVARIAN-CANCER
    AMOS, CI
    SHAW, GL
    TUCKER, MA
    HARTGE, P
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (14): : 1896 - 1899
  • [2] ORAL-CONTRACEPTIVES AND BREAST-CANCER RISK AMONG YOUNGER WOMEN
    BRINTON, LA
    DALING, JR
    LIFF, JM
    SCHOENBERG, JB
    MALONE, KE
    STANFORD, JL
    COATES, RJ
    GAMMON, MD
    HANSON, L
    HOOVER, RN
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11) : 827 - 835
  • [3] Breast cancer genes - What are the real risks?
    Easton, D
    [J]. NATURE GENETICS, 1997, 16 (03) : 210 - 211
  • [4] EASTON DF, 1995, AM J HUM GENET, V56, P265
  • [5] Jewish religion and risk of breast cancer
    Egan, KM
    Newcomb, PA
    Longnecker, MP
    TrenthamDietz, A
    Baron, JA
    Trichopoulos, D
    Stampfer, MJ
    Willett, WC
    [J]. LANCET, 1996, 347 (9016) : 1645 - 1646
  • [6] Kerber RA, 1997, AM J EPIDEMIOL, V146, P244
  • [7] BIAS IN USING FAMILY HISTORY AS A RISK FACTOR IN CASE-CONTROL STUDIES OF DISEASE
    KHOURY, MJ
    FLANDERS, WD
    [J]. EPIDEMIOLOGY, 1995, 6 (05) : 511 - 519
  • [8] LevyLahad E, 1997, AM J HUM GENET, V60, P1059
  • [9] The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%
    Oddoux, C
    Struewing, JP
    Clayton, CM
    Neuhausen, S
    Brody, LC
    Kaback, M
    Haas, B
    Norton, L
    Borgen, P
    Jhanwar, S
    Goldgar, D
    Ostrer, H
    Offit, K
    [J]. NATURE GENETICS, 1996, 14 (02) : 188 - 190
  • [10] RISCH N, 1984, AM J HUM GENET, V36, P363